Anthropic CEO Dario Amodei said AI could help cure most human diseases within five to 10 years, while arguing that the industry must deliver real breakthroughs in medicine and biology rather than rely on optimistic messaging to win public trust.

Amodei made the comments in a post on X, responding to criticism that his public messaging around AI has been disproportionately focused on the technology’s risks. He said he views his messaging as roughly balanced between AI’s benefits and dangers, citing his writing on the technology’s potential to transform health and biology.

Amodei said he wrote "Machines of Loving Grace" in 2024, in part, because he believed the AI industry was not painting a sufficiently inspiring picture of how technology could transform the world for the better. Much of that essay, he said, focused on challenging skepticism about AI’s potential in health and biology.

He said he believes AI could make it possible to "cure most human disease in ~5-10 years," acknowledging that the prediction may sound far-fetched to the public and even to biologists.

For Amodei, the potential medical impact is not simply about making AI more capable. He also pointed to the need for regulatory changes that would allow the healthcare system to keep pace with advances driven by AI.

In his more recent essay, "Policy on the AI Exponential," written in June 2026, Amodei said he proposed ways to streamline the Food and Drug Administration (FDA) process so that a wave of AI-accelerated drugs would not be unnecessarily slowed by regulation.

He said the issue carries a personal significance. Amodei’s father died from Hepatitis C only a few years before the development of direct-acting antiviral drugs such as sofosbuvir, which he said could cure 95% of patients and probably would have cured his father.

That experience appears to inform Amodei’s sense of urgency around AI’s potential in medicine. He said Anthropic is rapidly increasing its efforts in biology and medicine and expects to see "early glimmers" of progress in the coming months, followed by potentially more significant results in the years ahead.

At the same time, Amodei pushed back against the idea that the public’s skepticism toward AI can be solved through better marketing.

He said the public’s negative view of AI reflects what he described as a broader "crisis of trust," with people skeptical of companies, governments and the technology industry. In his view, simply telling people that AI will cure cancer is unlikely to restore that trust.

Instead, he argued that the industry needs to actually deliver on its promises.

"Actually curing cancer," Amodei said, would be more meaningful than a marketing campaign promising that AI could eventually do so. He said AI companies, including Anthropic, deserve criticism for not yet delivering on their biggest promises to benefit the world.

"That is totally on us, and I think it’s the criticism you should be making, instead of all this stuff about messaging and marketing," he said.

Amodei said Anthropic will publicize its achievements in biology and medicine when they materialize. Until then, he said he intends to continue speaking honestly about both AI’s potential benefits and its risks, arguing that credibility will ultimately come from tangible results rather than promises.

Photo: Shutterstock